Clinical Considerations for Immunotherapy

 
  • Specific

    Immunotherapy builds a population of immune cells over time that specifically target cancer cells1-4

    Learn more by watching Immunotherapy Is Tumor-Specific
    (2:10)

  • Adaptable

    The activated immune system adapts as cancer mutates, enabling it to recognize new tumor antigens2-3,5-6

    Learn more by watching Immunotherapy Is Designed to Support Immune System Adaptability
    (2:43)

  • Durable

    The immune system has memory and remains primed to stimulate a tumor-specific response1,7

    Learn more by watching Immunotherapy Empowers a Durable Immune Response
    (2:16)

Immunotherapy Is Tumor-Specific

 

Immunotherapy Is Designed to Support Immune System Adaptability

 

Immunotherapy Empowers a Durable Immune Response

 
 

Immunotherapy Is Different From Chemotherapy

Patients may respond differently to immunotherapy than to traditional cancer agents.

  • Immunotherapy targets the tumor over time, so although response may occur more slowly than with traditional cytotoxic therapies, the immune effect is potentially adaptable and durable2-4
  • RECIST criteria were designed to assess response to traditional cytotoxic agents so they are not as relevant for immunotherapy, which works differently2-4

Learn more by watching
Immunotherapy Works Differently
(2:40)

Immunotherapy Works Differently

 
 

It has been suggested that the relative efficacy of immunotherapy may be greater with a smaller tumor burden.3,8

Immunotherapy treatment may work best with lower tumor burdens
 

Immunotherapy Has Potential for Synergy

Since immunotherapy offers a different mechanistic approach than traditional therapies, there is potential for synergy with traditional therapies, such as chemotherapy and radiation.8-13

Several monoclonal antibodies that bind to specific targets on cancer cells when added to chemotherapy have been shown to improve survival, compared with chemotherapy alone.9-10